TREM Rx Pursues New Vaccine Science
This article was originally published in The Pink Sheet Daily
Executive Summary
A paper published in Nature reveals the paradigm-shifting science of TremRx’s vaccine technology.
You may also be interested in...
Hepatitis C, HIV, Antibiotics And Vaccines Headline Infectious Diseases Discussion At TAP Conference
In developing the infectious diseases track for this year’s Therapeutic Area Partnerships conference, planners focused on areas of unmet medical need, market potential, companies with a diversity of indications, strong science and multi-level partnering opportunities.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.